In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening.

ABSTRACT: Variability in patient response to anti-cancer drugs is currently addressed by relating genetic mutations to chemotherapy through precision medicine. However, practical benefits of precision medicine to therapy design are less clear. Even after identification of mutations, oncologists are often left with several drug options, and for some patients there is no definitive treatment solution. There is a need for model systems to help predict personalized responses to chemotherapeutics. We have microengineered 3D tumor organoids directly from fresh tumor biopsies to provide patient-specific models with which treatment optimization can be performed before initiation of therapy. We demonstrate the initial implementation of this platform using tumor biospecimens surgically removed from two mesoth

SUBMITTER: Mazzocchi AR 

PROVIDER: S-EPMC5811529 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature